{
 "drug": "Gemfibrozil Tablet",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "02/10/2026",
 "dayN": 196,
 "cat": "Endocrinology/Metabolism",
 "companies": [
  "Pfizer Inc."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "02/10/2026",
   "update_type": "New",
   "initial_posting_date": "02/10/2026",
   "package_ndc": "0071-0737-20",
   "generic_name": "Gemfibrozil Tablet",
   "contact_info": "800-533-4535",
   "related_info": "Discontinuation of the manufacture of the drug.",
   "openfda": {
    "application_number": [
     "NDA018422"
    ],
    "brand_name": [
     "LOPID"
    ],
    "generic_name": [
     "GEMFIBROZIL"
    ],
    "manufacturer_name": [
     "Parke-Davis Div of Pfizer Inc"
    ],
    "product_ndc": [
     "0071-0737"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "GEMFIBROZIL"
    ],
    "rxcui": [
     "205751",
     "310459"
    ],
    "spl_id": [
     "c2888455-2200-497a-8e5a-10515dcb4f66"
    ],
    "spl_set_id": [
     "c48855b7-215e-453b-b3b1-a0f9dee7221f"
    ],
    "package_ndc": [
     "0071-0737-20",
     "0071-0737-30"
    ],
    "nui": [
     "N0000175596",
     "N0000175375",
     "M0543661"
    ],
    "pharm_class_epc": [
     "Peroxisome Proliferator Receptor alpha Agonist [EPC]"
    ],
    "pharm_class_moa": [
     "Peroxisome Proliferator-activated Receptor alpha Agonists [MoA]"
    ],
    "pharm_class_cs": [
     "Fibric Acids [CS]"
    ],
    "unii": [
     "Q8X02027X3"
    ]
   },
   "update_date": "02/10/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Tablet",
   "presentation": "Lopid, Tablet, 600 mg (NDC 0071-0737-20)",
   "company_name": "Pfizer Inc.",
   "status": "To Be Discontinued"
  }
 ]
}